(HealthDay News) — Use of multiparametric 18fluorodeoxyglucose positron emission tomography magnetic resonance imaging (MP 18FDG PET-MRI) using dynamic contrast-enhanced MRI (DCE-MRI), diffusion-weighted imaging, three-dimensional proton MR spectroscopic imaging, and 18FDG-PET can improve differentiation of benign and malignant breast tumors, according to a study published online June 24 in Clinical Cancer Research.

Katja Pinker, MD, from the Medical University of Vienna, and colleagues examined whether MP 18FDG PET-MRI improves differentiation of benign and malignant breast tumors using data from 76 female patients with an imaging abnormality. Participants underwent fused PET-MRI of the breast. The likelihood of malignancy was compared for all single parameters, for MP MRI with two/three parameters, and for MP 18FDG PET-MRI, with histopathology as the standard of reference.

The researchers found that the area under the curve (AUC) was significantly higher with MP 18FDG PET-MRI than with DCE-MRI (0.935 vs. 0.86; P=0.044) and compared with the combination of DCE-MRI and a second parameter (AUC, 0.761–0.826; P=0.013 to 0.020). Further slight improvements were seen for MP 18FDG PET-MRI compared with MP MRI with three parameters (AUC, 0.925; P=0.317). Compared with use of MP imaging with one or two parameters, MP 18FDG PET-MRI would be associated with a reduction in unnecessary breast biopsies (P=0.002 to 0.011).

“This feasibility study shows that MP 18FDG PET-MRI enables an improved differentiation of benign and malignant breast tumors when several MRI and PET parameters are combined,” the authors write. “MP 18FDG PET-MRI may lead to a reduction in unnecessary breast biopsies.”

Full Text (subscription or payment may be required)